essentially flat compared with the first quarter of 2008. U.S. sales of Zyprexa increased 7 percent to $535.4 million, driven by higher prices and the favorable impact of wholesaler buying patterns, partially offset by lower demand. Zyprexa sales in international markets decreased 5 percent, to $587.6 million, driven by the unfavorable impact of foreign exchange rates, partially offset by increased volume. Demand outside the U.S. was favorably impacted by the withdrawal of generic competition in Germany.
Cymbalta
For the first quarter of 2009, Cymbalta generated $709.3 million in sales, an increase of 17 percent compared with the first quarter of 2008. U.S. sales of Cymbalta increased 17 percent, to $597.1 million, driven by higher demand, increased prices, and the favorable impact of wholesaler buying patterns. Sales outside the U.S. were $112.2 million, an increase of 19 percent, driven primarily by higher demand, partially offset by the unfavorable impact of foreign exchange rates.
Humalog
For the first quarter of 2009, worldwide Humalog sales increased 11 percent, to $450.6 million. Sales in the U.S. increased 20 percent to $286.2 million, driven by increased prices and increased demand. Sales outside the U.S. decreased 3 percent to $164.4 million, driven by the unfavorable impact of foreign exchange rates, partially offset by increased demand.
Gemzar
Gemzar sales totaled $367.8 million in the first quarter of 2009, a decrease of 14 percent from the first quarter of 2008. Sales in the U.S. decreased 4 percent, to $169.4 million, due to the unfavorable impact of wholesaler buying patterns and lower net effective selling prices, partially offset by higher demand. Sales outside the U.S. decreased 21 percent, to $198.3 million, as a result of the unfavorable impact of foreign exchange rates, reduced prices and the entry of generic competition in most major markets.
'/>"/>SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related medicine news :1.
Statement of Eli Lilly and Company on Dr. David Egilman Settlement:2.
Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division3.
Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar4.
Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets5.
Lillys CEO Calls for Reform of Nations Drug Safety System6.
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels7.
Lilly Grant to VA Will Enhance Services for Returning Combat Veterans8.
Lilly Delivers Strong Third-Quarter Results9.
Lilly and MacroGenics Announce Licensing and Collaboration Agreement10.
Eli Lilly and Company Aids California Recovery Effort11.
Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients